New therapies for MS such as mayzent and modified mesenchymal+ cells are developing. Siponimod was approved in 2019 for use in patients with secondary-progressive or relapsing-remitting form of MS. MSC+ immune-modulating therapies are also used to contain progression and reduce relapses.